C. SILAN Et Al. , "The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population," .European Human Genetics Conference , vol.20, no.1, Nürnberg, Germany, pp.1, 2012
SILAN, C. Et Al. 2012. The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population. .European Human Genetics Conference , (Nürnberg, Germany), 1.
SILAN, C., SILAN, F., ULUDAĞ, A., AŞGÜN, H. F., Atik, S., GÜNGÖR, B., ... AKSULU, H. E.(2012). The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population . .European Human Genetics Conference (pp.1). Nürnberg, Germany
SILAN, COŞKUN Et Al. "The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population," .European Human Genetics Conference, Nürnberg, Germany, 2012
SILAN, COŞKUN Et Al. "The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population." .European Human Genetics Conference , Nürnberg, Germany, pp.1, 2012
SILAN, C. Et Al. (2012) . "The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population." .European Human Genetics Conference , Nürnberg, Germany, p.1.
@conferencepaper{conferencepaper, author={COŞKUN SILAN Et Al. }, title={The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population}, congress name={.European Human Genetics Conference}, city={Nürnberg}, country={Germany}, year={2012}, pages={1} }